Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II first-in-human study of ISM3412 in MTAP-deleted advanced solid tumors
CTR20243737Phase 2Active
- Sponsor
- Insilico Medicine
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ISM3412 in Nonhematologic neoplasms, sponsored by Insilico Medicine. Started Apr 2025; status: active.
02
Drugs
ISM3412
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20243737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243737.